Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

James Chih‐Hsin Yang, Leah Haworth, Richard M. Sherry et al. · New England Journal of Medicine · 2003 · 2.7K citations · Full text

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2K citations

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

David H. Johnson, Louis Fehrenbacher, William Novotny et al. · Journal of Clinical Oncology · 2004 · 1.9K citations · Full text

Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line

Kohkichi Hata, Mitsuhiko Osaki, Dipok Kumar Dhar et al. · Cancer Chemotherapy and Pharmacology · 2003 · 34 citations

Oncology, Oncogenic Agent, Medicine +8